



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

18 August 2021

**DEPARTMENT MEMORANDUM**

No. 2021- 0367

**FOR: ALL DIRECTORS OF BUREAUS AND REGIONAL OFFICES, BARM, MINISTER OF HEALTH; CHIEFS OF MEDICAL CENTERS, HOSPITALS AND SANITARIA, AND OTHERS CONCERNED**

**SUBJECT: Health Technology Assessment Council's (HTAC) Updated Recommendations on COVID-19 Vaccine Sinovac**

By virtue of Republic Act 11223, otherwise known as the Universal Health Care (UHC) Act, health technology assessment (HTA) shall be institutionalized as a fair and transparent priority-setting mechanism to provide financing and coverage recommendations on health technologies to be funded by the Department of Health (DOH) and the Philippine Health Insurance Corporation (PhilHealth). Considering the public health emergency, the HTA Council (HTAC) aims to generate evidence-informed health technology recommendations amidst rapidly evolving evidence.


As such, please be informed that the Secretary of Health has approved the final HTAC recommendation on the following COVID-19 health technology:

1. SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the prevention of COVID-19 (July Updates)

To view the full evidence summary and rapid review of these recommendations, you may visit the HTA website at [hta.doh.gov.ph](http://hta.doh.gov.ph).

For your information and guidance.

By Authority of the Secretary of Health:

  
**GERARDO V. BAYUGO, MD, MPH, CESO I**  
Undersecretary of Health  
Health Regulation Team

